Approving a Problematic Muscular Dystrophy Drug: Implications for FDA Policy

Overview of attention for article published in JAMA: Journal of the American Medical Association, December 2016

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (83rd percentile)

So far, Altmetric has seen 7 Google+ posts from 4 users.

Approving a Problematic Muscular Dystrophy Drug: Implications for FDA Policy This Viewpoint discusses controversies surrounding…

Approving a Problematic Muscular Dystrophy Drug: Implications for FDA Policy This Viewpoint discusses controversies surrounding…

Approving a Problematic Muscular Dystrophy Drug: Implications for FDA Policy This Viewpoint discusses controversies surrounding…

Approving a Problematic Muscular Dystrophy Drug: Implications for FDA Policy This Viewpoint discusses controversies surrounding…

Approving a Problematic Muscular Dystrophy Drug: Implications for FDA Policy This Viewpoint discusses controversies surrounding…

Approving a Problematic Muscular Dystrophy Drug: Implications for FDA Policy This Viewpoint discusses controversies surrounding…

Patients with Duchenne muscular dystrophy (DMD), need better treatments, and drugs like eteplirsen might... Patients with…